stockrow
Friday 6 November 2026
Export MRVI’s income statement to Excel — free account
Maravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
7.52
0.54
+7.74%
Follow MRVI
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
5.36 | 4.42 | 2.02 | 2.53 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
227.69 | 231.34 | 47.82 | (20.61) | |
P/B ratio |
3.36 | 2.60 | 1.12 | 1.26 | |
Price to Tangible BV |
14.31 | 10.52 | 4.37 | 5.11 | |
EV/Sales |
5.85 | 4.93 | 2.54 | 3.09 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(244.37) | (40.78) | (13.14) | (9.97) | |
EV/FCF |
(99.31) | (28.74) | (9.87) | (8.12) | |
Quick Ratio |
2.99 | 2.63 | 4.68 | 5.40 | |
Current Ratio |
4.66 | 4.05 | 5.91 | 6.60 | |
Net Debt/EBITDA |
0.00 | (63.38) | 9.70 | (1.21) | |
Debt/Assets |
29.41% | 29.27% | 37.98% | 41.78% | |
Debt/Equity |
0.52 | 0.50 | 0.73 | 0.86 | |
Asset Turnover |
0.29 | 0.28 | 0.24 | 0.21 | |
Operating CF/Net income |
(0.36) | (0.32) | (2.32) | 0.64 | |
Capex/Depreciation |
0.00 | (0.03) | (0.34) | 0.08 | |
Interest Coverage |
(5.12) | (3.14) | (0.38) | (8.97) | |
Research and Development Expense of Revenue |
7.39% | 7.20% | 5.91% | 7.60% | |
Selling, General and Administrative Expense of Revenue |
66.52% | 62.34% | 44.19% | 63.05% | |
Intangible Assets out of Total Assets |
0.43 | 0.44 | 0.38 | 0.36 | |
Share Based Compensation of Revenue |
22.06% | 19.84% | 10.24% | 7.87% | |
Graham Net Nets |
(0.09) | (0.10) | (0.22) | (0.22) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.61%) | (8.33%) | (25.09%) | (27.69%) | |
Free Cash Flow Yield |
(1.10%) | (3.88%) | (12.69%) | (15.07%) | |
Revenue per Share |
0.31 | 0.35 | 0.45 | 0.35 | |
Operating CF per Share |
0.03 | 0.03 | 0.06 | (0.16) | |
Capex per Share |
0.00 | 0.00 | (0.03) | (0.01) | |
Free Cash Flow per Share |
0.03 | 0.02 | 0.03 | (0.17) | |
Cash per Share |
0.49 | 0.47 | 1.13 | 1.50 | |
Shareholders Equity per Share |
2.28 | 2.40 | 2.52 | 2.58 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.28 | 2.40 | 2.52 | 2.58 | |
Free Cash Flow |
4.49 | 3.62 | 4.23 | (24.88) | |
Working Capital |
120.94 | 117.24 | 209.11 | 251.33 | |
Capital Expenditures |
(0.52) | (0.37) | (4.44) | (2.11) | |
Net Current Asset Value |
(105.89) | (92.50) | (92.40) | (101.61) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.07 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
24.12 | 29.51 | 30.95 | 32.01 | |
Average Payables |
7.24 | 9.33 | 9.03 | 7.43 | |
Average Inventory |
44.29 | 43.95 | 45.12 | 45.29 | |
Average Assets |
724.63 | 750.36 | 836.48 | 889.41 | |
Average Common Equity |
386.01 | 411.79 | 449.68 | 474.96 |
Columns are period end dates · fundamentals updated 5 Nov 2026